Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr Christian Homsy, Chief Executive Officer, and members of the Company’s executive management team will present at the upcoming CAR-T Summit in Cambridge MA November 12-13, 2015.

The CAR-T Summit 2015 will see scientific and business leaders from pharma, biotech, academia and the service community gather to discuss clinical strategy, scalable manufacture and global commercial viability, to accelerate the clinical development and scalable economic manufacture of CAR-T cell therapies.

Celyad’s management will participate at the following sessions during the summit:

Dr. Christian Homsy will speak as part of the keynote address panel on "How the CAR-T community can avoid another 'Biologics Bubble' and deliver on the early clinical promise".  This important discussion will focus on connecting clinical aspirations with the current facts of
CAR-T therapies.

Dr. Frederic Lehmann, VP of Immuno-Oncology at Celyad, will host a panel discussing how to translate early signals in liquid tumors to solid tumors.  This session will explore what lessons have been learned so far and the potential success factors for expanding the utility of CAR-T therapy across all cancer categories.

Steve Buckanavage, VP of Global Marketing at Celyad, will host a roundtable discussion on "Bringing economically viable CAR therapy to market".  As pipelines mature and marketing plans are being readied, this session will explore how the CAR-T industry can engage Health Authorities and Payers to bridge from registration to reimbursement for this new class of therapies.

Download press release(s)

Press release

300.60 Ko

Communiqué de presse

349.30 Ko

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CA...

Next News

Celyad successfully completes 30-day safety follow-up of first patient cohort in NKG2D CA...